Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 15,303.10 +8.60 0.06%
S&P 500 1,649.60 -0.91 -0.06%
Nasdaq 3,459.14 -0.27 -0.01%
Ticker Volume Price Price Delta
STOXX 50 2,764.29 -12.49 -0.45%
FTSE 100 6,654.34 -42.45 -0.63%
DAX 8,305.32 -46.66 -0.56%
Ticker Volume Price Price Delta
Nikkei 14,612.50 +128.47 0.89%
Hang Seng 22,618.70 -51.01 -0.23%
S&P/ASX 200 4,983.50 -78.95 -1.56%
  • Exchange: NASDAQ GS
  • Sector: Consumer, Non-cyclical
  • Industry: Pharmaceuticals
  • Sub-Industry: Therapeutics

Synageva BioPharma Corp

+ Add to Watchlist

GEVA:US

40.8800 USD 0.2900 0.71%

As of 20:10:00 ET on 05/24/2013.

Company Profile for Synageva BioPharma Corp (GEVA)

Synageva BioPharma Corp. is a clinical stage biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and unmet medical need.

Contact Information

Synageva BioPharma Corp

128 Spring Street
Suite 520
Lexington, MA 02421
United States
Phone: 1-781-357-9900
Fax: 1-781-357-9901

Key Executives for Synageva BioPharma Corp (GEVA)

Sanj K PatelPresident/CEO/SecretaryCarsten BoessSenior VP/CFO
Anthony G QuinnSenior VP/Chief Medical OffcrMarc E GoldbergSenior VP:Product Dev
Glen WilliamsSenior VP:Global Technical Ops

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Advertisements
Advertisement
sec ||= nil